Srihari  S.  Naidu,  MD

Interventional Cardiology &

Hypertrophic Cardiomyopathy

914 598 7651 (westchester)

516 307 9388 (long island)

Srihari S. Naidu, MD, is an interventional cardiology expert in both the minimally-invasive treatments of heart disease and hypertrophic cardiomyopathy, the most common cause of death in athletes and a common cause of heart failure at all ages.  He is skilled in atrial septal defect (ASD) and patent foramen ovale (PFO) closure, alcohol septal ablation for hypertrophic obstructive cardiomyopathy, aortic and mitral valvuloplasty (and mitraclip percutaneous valve repair), ventricular assist devices, left atrial appendage occlusion, and coronary intervention including angioplasty and stent placement.  He is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

Prior to joining Westchester Medical Center in 2016, Dr. Naidu was an Assistant Professor of Medicine at New York Presbyterian Hospital - Weill Cornell Medical Center and then an Associate Professor of Medicine at SUNY Stony Brook.  Dr. Naidu developed the Hypertrophic Cardiomyopathy Treatment Center at Cornell, performing their first series of alcohol septal ablations, and then grew it to over 800 patients and over 130 alcohol ablations while making it a national Center of Excellence at Winthrop.  Dr. Naidu trained in Internal Medicine at Cornell, and General and Interventional Cardiology at the University of Pennsylvania.  

A graduate of the 8-year Program in Liberal Medical Education at Brown University, Dr. Naidu is Past President of the Medical School Board of Directors, and Reunion Chair of the Undergraduate Class of 1993. He currently serves as Trustee on the Brown University Corporation.

In 2016, Dr. Naidu was recruited to Westchester Medical Center to assist the Interventional Cardiology program, as well as Interventional Heart Failure initiatives, and to Direct the HCM Program, with office locations in Long Island and Westchester.  He is also the Director of the Cardiac Catheterization Laboratories.  With respect to HCM in particular, the Center has two offices for patients, and will serve one of the largest regions of the country, spanning Upstate NY, Western MA, Western CT, Long Island, the five boroughs of NYC, and parts of Northern and Central NJ.  The Program received National Center of Excellence designation from the Hypertrophic Cardiomyopathy as one of 30 such centers nationwide.

A Fellow of the American College of Cardiology (FACC), American Heart Association (FAHA), and Society for Cardiovascular Angiography and Interventions (FSCAI), Dr. Naidu serves on several national committees, including the ACC Interventional Science Council (two term member) and Curriculum Design Committee, and is an Associate Director for TCT.  Dr. Naidu Founded the SCAI Emerging Leader Mentorship (ELM) Program in partnership with ACC and the Cardiovascular Research Foundation (CRF), a dedicated interventional leadership pipeline that selects and mentors 10 interventional cardiologists every 2 years for national leadership roles.  He is currently Co-Chair of Development and Industry Relations for SCAI and on the Board of Directors of the International Andreas Gruentzig Honor Society.


Dr. Naidu has over 100 scientific publications, and regularly lectures throughout the United States.  He is the Editor of two textbooks - Hypertrophic Cardiomyopathy, by Springer, now in its 2nd Edition, and Interventional Heart Failure, by Elsevier. In addition, he routinely serves as Invited Speaker for the American College of Cardiology (ACC), American Heart Association (AHA), Transcatheter Cardiovascular Therapeutics (TCT), and Society for Cardiac Angiography and Intervention (SCAI) Scientific Sessions.  For his academic leadership and engagement in research, clinical care and education, Dr. Naidu was promoted to Professor of Medicine (Tenure) at New York Medical College in 2018, the highest academic rank.